Epitomics, Inc. announced today that it has signed a service agreement with Bayer Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody technology to produce antibodies for Bayer HealthCare's drug target identification and validation.
"Epitomics has had a long-standing experience with Bayer HealthCare. This new agreement is a major expansion of our collaboration and confirms the success of our premium technology platform," said Guo-Liang Yu, PhD, CEO of Epitomics, Inc.
"Our recent experience with the Epitomics rabbit antibody technology has been impressive and we are very pleased to be expanding our collaboration with Epitomics," said Clive R. Wood, Ph.D., Senior VP and Head of Global Biologics, Bayer HealthCare.
Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity, specificity and bioactivity both in vitro and in vivo. Epitomics, Inc. is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.